<DOC>
	<DOCNO>NCT02323854</DOCNO>
	<brief_summary>Post market prospective , non-randomized , single-arm , multicenter study , design demonstrate dose response ablation system use percutaneous approach patient primary , metastatic , recurrent primary lung tumor .</brief_summary>
	<brief_title>The EMPrint™ Ablate RESect Study Patients With Metastatic Lung Tumors ( EMPRESS )</brief_title>
	<detailed_description>Primary Endpoint : Dose response indicate CT imaging , measurement maximum diameter volume . Secondary Endpoint : Assessment complete tumor ablation immediately post-procedure .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Subject authorize representative provide informed consent . Subject ≥18 year age . At least one pulmonary metastasis ≤ 3.0 cm maximum diameter result distant primary cancer least one recurrence primary lung cancer ≤ 3.0 cm maximum diameter . Subject confirm thoracic surgeon surgical candidate resection tumor target ablation . Subject willing able comply aspect treatment evaluation schedule . ≥1 cm tumorfree lung parenchyma target tumor pleura fissure . Preprocedure Exclusion Criteria Contraindicated surgery . Prolonged chest infection , define lung consolidation require hospitalization great 10 day antibiotics 30 day prior surgery . Tumor abut main stem bronchus , main pulmonary artery branch , esophagus and/or trachea . Tumor pleural contact . Tumors locate &lt; 3 cm staple line metal object . Patients diagnose GOLD Stage IV Emphysema . Uncontrollable coagulopathy Patients unable tolerate discontinue use anticoagulant prior ablation procedure . Subject pregnant ( documented positive pregnancy test accord hospital standard practice ) actively breastfeed . Subject participate investigational drug device research study within 30 day enrollment would interfere study . The investigator determine participation study may jeopardize safety welfare subject . Patients implantable pacemaker electronic implant , accordance Instructions Use ( IFU ) . Intraprocedural Exclusion Criteria *Incidental intraprocedural finding subject long meet study eligibility criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>primary , recurrent , metastatic lung tumor , ablation</keyword>
</DOC>